Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab in patients with severe asthma who failed to respond to omalizumab: a pilot study
2016-004459-65Phase 2Active
- Sponsor
- Respira Therapeutics
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of reslizumab in severe asthma, asthma, sponsored by Respira Therapeutics. Started Feb 2017; status: active.
02
Drugs
reslizumab
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on 2016-004459-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004459-65.